Type I Interferon Receptor Expression in Human Pancreatic and Periampullary Cancer Tissue
| Autor: | van Koetsveld Pm, van Eijck Ch, Katharina Biermann, Hofland Lj, Croze E, de Vogel L, Waaijers Am, Booy S |
|---|---|
| Přispěvatelé: | Surgery, Internal Medicine, Pathology |
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Ampulla of Vater Time Factors Endocrinology Diabetes and Metabolism medicine.medical_treatment Receptor expression Common Bile Duct Neoplasms Kaplan-Meier Estimate Receptor Interferon alpha-beta Endocrinology SDG 3 - Good Health and Well-being Predictive Value of Tests Pancreatic cancer Internal medicine Internal Medicine medicine Periampullary cancer Biomarkers Tumor Humans Receptor Aged Neoplasm Staging Proportional Hazards Models Aged 80 and over Hepatology business.industry Cancer Middle Aged medicine.disease people.cause_of_death Immunohistochemistry Pancreatic Neoplasms Treatment Outcome Cancer research CA19-9 Female business people Adjuvant |
| Zdroj: | Pancreas, 44(1), 99-105. Lippincott Williams & Wilkins |
| ISSN: | 1536-4828 0885-3177 |
| Popis: | Objectives: Interferons (IFNs) have several anticancer mechanisms. A number of clinical trials have been conducted regarding adjuvant IFN-α therapy in pancreatic cancer. Type I IFNs exert their effect via the type I IFN receptor (IFNAR-1, IFNAR-2c). The aims of the present studywere to determine the type I IFN receptor expression in pancreatic and periampullary cancer tissues and to study its relation with clinicopathological factors. Methods: Receptor expression was determined by immunohistochemistry in paraffin-embedded cancer tissue of 47 pancreatic and 54 periampullary cancer patients. Results: The results demonstrated that 91.5% of the pancreatic tumors and 88.9% of the periampullary tumors showed expression of IFNAR-1, of which 23.4% and 13.0% were strongly positive, respectively. Regarding IFNAR-2c expression, 68.1% of the pancreatic tumors and 68.5% of the periampullary tumors were positive, of which 4.3% of the pancreatic tumors and none of the periampullary tumors had a strong expression. No statistically significant associations were found between type I IFN receptor expression and clinicopathological factors or survival. Conclusions: Type I IFN receptors are expressed in pancreatic and periampullary cancer tissues although with great intertumoral and intratumoral variability. A small proportion of both tumors showed a strong expression of the IFNAR-1; only a very small percentage of the pancreatic tumors showed strong expression of the IFNAR-2c. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|